{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:26:09Z","timestamp":1787725569078,"version":"build-2784847793"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T00:00:00Z","timestamp":1786147200000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100030924","name":"Kaiser Permanente Southern California","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030924","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Consensus definitions for clinical identification of invasive aspergillosis (IA) are lacking, likely owing to difficulties in diagnosis. While the European Organisation for Research and Treatment of Cancer\u2013Mycoses Study Group (EORTC\/MSG) has provided benchmark guidelines to define IA, the criteria are highly restrictive. In this study, we constructed alternative definitions of IA using structured data from electronic health records (EHRs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>From October 1, 2015, to March 31, 2022, we identified patients with IA from EHRs at Kaiser Permanente Southern California using definitions comprised of combinations of diagnosis codes, antifungal prescriptions, and\/or positive mycological findings. Here, we report patient characteristics, including demographic information, underlying comorbidities, and immunosuppression, diagnostic measures, and morbidity and mortality after diagnosis for the population comprising each IA definition.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Between 86 and 4580 individuals were identified as possible IA cases across 7 definitions. All IA definitions that except for that only required positive mycology had similar patient characteristics and outcomes to those meeting 2008 EORTC\/MSG criteria. The largest of these cohorts was comprised of 1067 patients, compared with the 86 that met EORTC\/MSG criteria. Across IA definitions, all-cause mortality ranged from 11.7% to 33.1% within 6 months following diagnosis. The number of IA cases began trending upward between 2019 and 2020 and continued steadily through the coronavirus disease 2019 pandemic.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>IA definitions based on structured data can increase efficiency and identify clinically significant IA cases that might otherwise go unrepresented. Variability in the number of patients identified between definitions further highlights critical deficits in current IA diagnostics.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ofid\/ofag478","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T11:48:32Z","timestamp":1786016912000},"source":"Crossref","is-referenced-by-count":0,"title":["Identification of Invasive Aspergillosis in Electronic Health Records"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3369-3475","authenticated-orcid":false,"given":"Emily","family":"Rayens","sequence":"first","affiliation":[{"name":"Department of Research & Evaluation, Kaiser Permanente Southern California , Pasadena, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Skela","sequence":"additional","affiliation":[{"name":"Department of Research & Evaluation, Kaiser Permanente Southern California , Pasadena, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0816-7345","authenticated-orcid":false,"given":"Bradley K","family":"Ackerson","sequence":"additional","affiliation":[{"name":"Department of Research & Evaluation, Kaiser Permanente Southern California , Pasadena, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7280-9084","authenticated-orcid":false,"given":"Magdalena E","family":"Pomichowski","sequence":"additional","affiliation":[{"name":"Department of Research & Evaluation, Kaiser Permanente Southern California , Pasadena, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lance B","family":"Price","sequence":"additional","affiliation":[{"name":"Department of Environmental and Occupational Health, George Washington University , Washington, DC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2336-8476","authenticated-orcid":false,"given":"Sara Y","family":"Tartof","sequence":"additional","affiliation":[{"name":"Department of Research & Evaluation, Kaiser Permanente Southern California , Pasadena, California ,","place":["USA"]},{"name":"Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine , Pasadena, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,8]]},"reference":[{"key":"2026082601463117300_ofag478-B1","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1093\/cid\/ciy776","article-title":"Estimation of direct healthcare costs of fungal diseases in the United States","volume":"68","author":"Benedict","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2026082601463117300_ofag478-B2","doi-asserted-by":"crossref","first-page":"XXX","DOI":"10.1093\/ofid\/ofab593","article-title":"Prevalence and healthcare burden of fungal infections in the United States, 2018","volume":"9","author":"Rayens","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2026082601463117300_ofag478-B3","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1086\/651262","article-title":"Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET)","volume":"50","author":"Pappas","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2026082601463117300_ofag478-B4","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ijantimicag.2011.11.017","article-title":"Invasive fungal infections in patients with cancer in the intensive care unit","volume":"39","author":"Sipsas","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"2026082601463117300_ofag478-B5","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.3899\/jrheum.111498","article-title":"Invasive fungal infections in patients with systemic lupus erythematosus","volume":"39","author":"Martinez-Martinez","year":"2012","journal-title":"J Rheumatol"},{"key":"2026082601463117300_ofag478-B6","doi-asserted-by":"crossref","first-page":"e003281","DOI":"10.1136\/rmdopen-2023-003281","article-title":"Invasive fungal diseases in patients with autoimmune diseases: a case series from the French RESSIF network","volume":"9","author":"Galmiche","year":"2023","journal-title":"RMD Open"},{"key":"2026082601463117300_ofag478-B7","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1182\/blood-2003-02-0456","article-title":"Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning","volume":"102","author":"Fukuda","year":"2003","journal-title":"Blood"},{"key":"2026082601463117300_ofag478-B8","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1164\/rccm.200401-093OC","article-title":"Invasive aspergillosis in critically ill patients without malignancy","volume":"170","author":"Meersseman","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"2026082601463117300_ofag478-B9","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1093\/jac\/dkaa518","article-title":"Validation of the EQUAL aspergillosis score by analysing guideline-adherent management of invasive pulmonary aspergillosis","volume":"76","author":"Budin","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2026082601463117300_ofag478-B10","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/cid\/ciab336","article-title":"Mortality trends in risk conditions and invasive mycotic disease in the United States, 1999-2018","volume":"74","author":"Rayens","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2026082601463117300_ofag478-B11","doi-asserted-by":"crossref","first-page":"106882","DOI":"10.1016\/j.rmed.2022.106882","article-title":"Autopsy study of fatal invasive pulmonary aspergillosis: often undiagnosed premortem","volume":"199","author":"Mudrakola","year":"2022","journal-title":"Respir Med"},{"key":"2026082601463117300_ofag478-B12","doi-asserted-by":"crossref","first-page":"XXX","DOI":"10.1093\/ofid\/ofab174","article-title":"Limited index of clinical suspicion and underdiagnosis of histopathologically documented invasive mold infections","volume":"8","author":"Caudron de Coquereaumont","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2026082601463117300_ofag478-B13","doi-asserted-by":"crossref","first-page":"XXX","DOI":"10.1093\/ofid\/ofz176","article-title":"Incidence and risk factors for breakthrough invasive mold infections in acute myeloid leukemia patients receiving remission induction chemotherapy","volume":"6","author":"Patel","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2026082601463117300_ofag478-B14","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1128\/JCM.36.6.1494-1500.1998","article-title":"Molecular typing of environmental and patient isolates of Aspergillus fumigatus from various hospital settings","volume":"36","author":"Chazalet","year":"1998","journal-title":"J Clin Microbiol"},{"key":"2026082601463117300_ofag478-B15","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1080\/02681219880000241","article-title":"Concentrations of airborne Aspergillus compared to the incidence of invasive aspergillosis: lack of correlation","volume":"36","author":"Hospenthal","year":"1998","journal-title":"Med Mycol"},{"key":"2026082601463117300_ofag478-B16","doi-asserted-by":"crossref","first-page":"37","DOI":"10.7812\/TPP\/12-031","article-title":"Sociodemographic characteristics of members of a large, integrated health care system: comparison with US Census Bureau data","volume":"16","author":"Koebnick","year":"2012","journal-title":"Perm J"},{"key":"2026082601463117300_ofag478-B17","author":"Kaiser Permanente Southern California Department of Research & Evaluation"},{"key":"2026082601463117300_ofag478-B18","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","article-title":"Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) Consensus Group","volume":"46","author":"De Pauw","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2026082601463117300_ofag478-B19","doi-asserted-by":"crossref","first-page":"XXX","DOI":"10.1093\/ofid\/ofae594","article-title":"Identifying gaps in the international consensus case definitions for invasive aspergillosis: a review of clinical cases not meeting these definitions","volume":"11","author":"Tio","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"2026082601463117300_ofag478-B20","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1007\/s00134-020-06219-8","article-title":"Bacterial and fungal superinfections in critically ill patients with COVID-19","volume":"46","author":"Bassetti","year":"2020","journal-title":"Intensive Care Med"},{"key":"2026082601463117300_ofag478-B21","doi-asserted-by":"crossref","first-page":"XXX","DOI":"10.1093\/ofid\/ofab510","article-title":"Coronavirus disease 2019-associated invasive fungal infection","volume":"8","author":"Baddley","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2026082601463117300_ofag478-B22","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12866-024-03267-8","article-title":"Hospital distribution, seasonality, time trends and antifungal susceptibility profiles of all Aspergillus species isolated from clinical samples from 2015 to 2022 in a tertiary care hospital","volume":"24","author":"Franconi","year":"2024","journal-title":"BMC Microbiol"},{"key":"2026082601463117300_ofag478-B23","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.jiac.2019.10.020","article-title":"Seasonal changes in indoor airborne fungal concentration in a hematology ward","volume":"26","author":"Mori","year":"2020","journal-title":"J Infect Chemother"},{"key":"2026082601463117300_ofag478-B24","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1086\/652761","article-title":"Geoclimatic influences on invasive aspergillosis after hematopoietic stem cell transplantation","volume":"50","author":"Panackal","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2026082601463117300_ofag478-B25","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2026082601463117300_ofag478-B26","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/art.42386","article-title":"2022 American College of Rheumatology guideline for vaccinations in patients with rheumatic and musculoskeletal diseases","volume":"75","author":"Bass","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"2026082601463117300_ofag478-B27","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1016\/S2666-5247(22)00261-0","article-title":"The current state of laboratory mycology and access to antifungal treatment in Europe: a European Confederation of Medical Mycology survey","volume":"4","author":"Salmanton-Garcia","year":"2023","journal-title":"Lancet Microbe"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofag478\/70554921\/ofag478.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/8\/ofag478\/70554921\/ofag478.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/8\/ofag478\/70554921\/ofag478.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T05:46:45Z","timestamp":1787723205000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofag478\/8756897"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofag478","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,8,1]]},"article-number":"ofag478"}}